Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 148 No. 3738 (2018)

Adult onset haemophagocytic lymphohistiocytosis prognosis is affected by underlying disease: analysis of a single-institution series of 174 patients

  • Qiaolei Zhang
  • Li Li
  • Lixia Zhu
  • Jingjing Zhu
  • Xiudi Yang
  • De Zhou
  • Yanglong Zheng
  • Mingyu Zhu
  • Mixue Xie
  • Jianai Sun
  • Xueying Li
  • Ying Wu
  • Zhangyue Wei
  • Wanzhuo Xie
  • Xiujin Ye
DOI
https://doi.org/10.4414/smw.2018.14641
Cite this as:
Swiss Med Wkly. 2018;148:w14641
Published
23.09.2018

Summary

BACKGROUND

Haemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome characterised by activation of the mononuclear phagocytic system, and often leads to progressive multiple organ failure. The diagnosis of HLH is made late by most physicians.

METHODS

To confirm the diagnosis of acquired HLH made in a single-institution series of adult patients with HLH-04 criteria, we applied the HScore and evaluated prognostic factors associated with clinical outcome.

RESULTS

A total of 174 patients with a median age of 51 years (range 17–90) were included. Male/female ratio was 111/63. In 92/174 (52.9%) patients, there were potential haematological diseases (4 acute leukaemia, 1 thrombotic thrombocytopenic purpura, 3 Hodgkin’s lymphoma [HL], 17 B-cell non-Hodgkin’s lymphoma [NHL], 67 T-cell NHL including 22 natural killer / T-cell NHL [NK/t-cell NHL). Six (3.4%) patients had autoimmune disease and 76 (43.7%) undiagnosed underlying disease. There were 44 (25.3%) patients with Epstein-Barr virus infection, 11 (6.3%) with cytomegalovirus, 1 (0.5%) syphilis, 9 (5.2%) hepatitis B virus and 3 (1.7%) human immunodeficiency virus. More than 95% of patients had hyperferritinaemia, high lactate dehydrogenase, fever and low albumin, whereas 89.1% of patients had bone marrow phagocytosis. By the HScore, 4/174 patients had a >50% and 16/174 patients had a >90% probability of not having HLH. All 174 patients fulfilled more than five of the HLH-04 diagnostic criteria, but 16 of them had a low probability of HLH by the HScore. In a multivariate analysis, lymphopenia and hypofibrinogenaemia were independent prognostic factors for death.

CONCLUSION

In our study, viral infection was not an independent prognostic factor. NK/T-cell -NHL was associated with worse prognosis compared with B-cell NHL and T-cell NHL (p = 0.036) and similar to other aetiologies.

References

  1. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015;26(3):263–80. doi:.https://doi.org/10.1016/j.cytogfr.2014.10.001
  2. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86. doi:.https://doi.org/10.2147/JBM.S46255
  3. Shabbir M, Lucas J, Lazarchick J, Shirai K. Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol. 2011;29(2):100–6. doi:.https://doi.org/10.1002/hon.960
  4. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31. doi:.https://doi.org/10.1002/pbc.21039
  5. Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51(3):402–4. doi:.https://doi.org/10.1002/pbc.21564
  6. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52. doi:.https://doi.org/10.1182/blood-2011-03-278127
  7. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–16. doi:.https://doi.org/10.1016/S0140-6736(13)61048-X
  8. Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child. 2011;96(7):688–93. doi:.https://doi.org/10.1136/adc.2009.176610
  9. Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al.; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84. doi:.https://doi.org/10.1182/blood-2011-06-356261
  10. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63(1):233–46. doi:.https://doi.org/10.1146/annurev-med-041610-134208
  11. Arca M, Fardet L, Galicier L, Rivière S, Marzac C, Aumont C, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168(1):63–8. doi:.https://doi.org/10.1111/bjh.13102
  12. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86(1):58–65. doi:.https://doi.org/10.1532/IJH97.07012
  13. Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484–92. doi:.https://doi.org/10.1016/j.mayocp.2013.12.012
  14. Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O, et al. Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. Am J Med. 2014;127(11):1118–25. doi:.https://doi.org/10.1016/j.amjmed.2014.04.034
  15. Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90(3):220–4. doi:.https://doi.org/10.1002/ajh.23911
  16. Li J, Wang Q, Zheng W, Ma J, Zhang W, Wang W, et al. Hemophagocytic lymphohistiocytosis: clinical analysis of 103 adult patients. Medicine (Baltimore). 2014;93(2):100–5. doi:.https://doi.org/10.1097/MD.0000000000000022
  17. Li F, Li P, Zhang R, Yang G, Ji D, Huang X, et al. Identification of clinical features of lymphoma-associated hemophagocytic syndrome (LAHS): an analysis of 69 patients with hemophagocytic syndrome from a single-center in central region of China. Med Oncol. 2014;31(4):902. doi:.https://doi.org/10.1007/s12032-014-0902-y
  18. Takahashi N, Chubachi A, Kume M, Hatano Y, Komatsuda A, Kawabata Y, et al. A clinical analysis of 52 adult patients with hemophagocytic syndrome: the prognostic significance of the underlying diseases. Int J Hematol. 2001;74(2):209–13. doi:.https://doi.org/10.1007/BF02982007
  19. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20. doi:.https://doi.org/10.1002/art.38690
  20. Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2016;75(3):481–9. doi:.https://doi.org/10.1136/annrheumdis-2015-208982
  21. Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016;172(3):412–9. doi:.https://doi.org/10.1111/bjh.13837
  22. Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly. 2005;135(21-22):299–314.
  23. Yu JT, Wang CY, Yang Y, Wang RC, Chang KH, Hwang WL, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis: experience in adults from a single institution. Ann Hematol. 2013;92(11):1529–36. doi:.https://doi.org/10.1007/s00277-013-1784-3
  24. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493–8. doi:.https://doi.org/10.1007/s00277-007-0278-6
  25. Gavand PE, Serio C, Larroche N, Costedoat-Chalumeau C, Lavigne L, Mouthon M, et al. Association syndrome lymphohystiocytaire (HLH) et lupus systémique: étude multicentrique française de 103 épisodes chez 89 patients adultes. Rev Med Interne. 2016;37:A122–3. doi:.https://doi.org/10.1016/j.revmed.2016.10.106
  26. Ruscitti P, Cipriani P, Di Benedetto P, Ciccia F, Liakouli V, Carubbi F, et al. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still’s disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmun Rev. 2015;14(5):429–37. doi:.https://doi.org/10.1016/j.autrev.2015.01.004
  27. Shin HJ, Chung JS, Lee JJ, Sohn SK, Choi YJ, Kim YK, et al. Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci. 2008;23(3):439–44. doi:.https://doi.org/10.3346/jkms.2008.23.3.439
  28. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012;13(4):289–98. doi:.https://doi.org/10.1038/gene.2012.3
  29. Wang Y, Huang W, Wei N, Zeng X, Zhang J, Wang J, et al. [Clinical study of DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(10):901–4. Article in Chinese.